Akebia Therapeutics (AKBA) presents a deeply negative liquidation posture. As of March 31, 2026, total assets are $362.5M against total liabilities of $335.1M, leaving book equity of $27.4M. Under liquidation haircuts, the recovery picture collapses: cash of $162.6M recovers at par; gross AR of ~$65.4M (net $62.5M, with $2.9M allowance) recovers at ~90-95%, yielding ~$59-62M; current inventory of $13.0M and non-current inventory of $56.1M together total ~$69.1M and recover at roughly 60%, or ~$41.5M; PP&E net of $1.0M recovers at ~50-70%, or ~$0.5-0.7M; goodwill of $59.0M and ROU assets of $2.5M recover at zero; other non-current assets of $56.6M (predominantly non-current inventory) are already captured in the inventory haircut. Against these haircutted assets, liabilities stand at face: current liabilities of $173.9M include accrued liabilities of $125.1M (dominated by a gross-to-net refund liability/reserve balance of $82.6M, chargebacks, rebates), current debt of $12.5M, deferred revenue of $4.5M, and the current refund liability of $23.4M. Long-term liabilities of $161.3M include the BlackRock credit facility with gross carrying amount of $52.4M ($48.9M net of discount/issuance costs), a non-current refund liability of $16.4M, a derivative liability of $2.5M, and other non-current liabilities. MFFAIS-computed CLV is negative $47.6M, LLV is approximately $14.9M, and OLV is $27.9M, consistent with the narrow positive book equity that evaporates once intangibles and goodwill are zeroed. Key drivers of the negative/marginal liquidation posture: (1) $59.0M of goodwill from the 2018 Merger recovers at zero; (2) $82.6M gross valuation reserve against gross-to-net liabilities is the dominant current liability item and stays at face in liquidation; (3) non-current inventory of $56.1M reflects Vafseo build-ahead and Auryxia authorized-generic stock with uncertain realization under liquidation conditions — the 60% haircut is the key swing variable; (4) $52.4M gross debt (Kreos/BlackRock facility) stays at face. The company generated negative operating cash flow of $21.2M in Q1 2026 and burned $22.2M of cash in the period. Auryxia is now facing authorized-generic and Teva generic competition post-LoE (March 2025 entry for authorized generic; Teva ANDA approved March 2026). Vafseo launched January 2025 under TDAPA reimbursement, which is time-limited (two years from Jan 2025). The filing discusses material production commitments with WuXi STA and Patheon but does not separately XBRL-tag those contractual purchase obligations; they appear only in the MD&A/risk factor narrative.
▼ Community Notes